Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2010, Pages 126-131

  Kim, Hyunmi ^a   Bae, Soo Kyung ^a,b   Park, Soo Jin ^a   Shim, Eon Jeong ^a   Kim, Ho Sook ^a   Shon, Ji Hong ^a,b   Liu, Kwang Hyeon ^a   Shin, Jae Gook ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

4 hydroxybupropion; Bupropion; CYP2B6; Drug interaction; Woohwangcheongsimwon suspension

Indexed keywords

4 HYDROXYBUPROPION; AMFEBUTAMONE; CYTOCHROME P450 2B6; HERBACEOUS AGENT; UNCLASSIFIED DRUG; WOOHWANGCHEONGSIMWON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG METABOLISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BUPROPION; CROSS-OVER STUDIES; DRUGS, CHINESE HERBAL; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; SUSPENSIONS; YOUNG ADULT;

EID: 77953504763     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03661.x     Document Type: Article

References (19)

1. Korea Food and Drug Administration. In : Korean Pharmaceutical Codex, 3rd edn.
2. Kim H, Kim KB, Ku HY, Park SJ, Choi H, Moon JK, Park BS, Kim JH, Su Yea S, Lee CH, Lee HS, Shin JG, Liu KH. Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China. Drug Metab Dispos 2008 36 : 1010 1015.
3. Seo KA, Kim H, Ku HY, Ahn HJ, Park SJ, Bae SK, Shin JG, Liu KH. The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chem Biol Interact 2008 174 : 141 146.
4. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000 28 : 1176 1183.
5. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000 28 : 1222 1230.
6. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 2001 29 : 1123 1129.
7. Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006 80 : 75 84.
8. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005 77 : 553 559.
9. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003 74 : 326 333.
10. Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007 81 : 69 75.
11. Shin YW, Erm TM, Choi EJ, Kim SY. A case of prolonged seizure activity after combined use of bupropion and clomipramine. Clin Neuropharmacol 2004 27 : 192 194.
12. Kramer HJ, Ulmer HV. Reference values for body fat content as a measure for desirable body fat content. Z Ernahrungswiss 1984 23 : 1 11.
13. Rohrbacher M, Kirchhof A, Geisslinger G, Lotsch J. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics 2006 7 : 995 1002.
14. Coles R, Kharasch ED. Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007 857 : 67 75.
15. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004 57 : 592 599.
16. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 2003 45 : 122 132.
17. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003 13 : 619 626.
18. McLean S, Boyle RR, Brandon S, Davies NW, Sorensen JS. Pharmacokinetics of 1,8-cineole, a dietary toxin, in the brushtail possum (Trichosurus vulpecula): significance for feeding. Xenobiotica 2007 37 : 903 922.
19. Bhatia SP, Letizia CS, Api AM. Fragrance material review on borneol. Food Chem Toxicol 2008 46 (Suppl. 11 S77 80.